Alvotech and JAMP Pharma have entered into an agreement for an exclusive partnership to supply and commercialize five biosimilar candidates in the Canadian market. The current market value of the branded sales for these biosimilars is estimated to exceed $2 billion annually.   The partnership agreement includes the exclusive rights for JAMP Pharma to commercialize Alvotech’s biosimilars in Canada, leveraging JAMP’s sales and marketing capabilities and experience in successfully bringing new bios...